References
- The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316–321.
- Main ML, Ramaswamy K, Andrews TC. Cardiac arrest and myocardial infarction immediately after sumatriptan injection. Ann Intern Med. 1998;128(10):874–875.
- MacIntyre PD, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87:401–405.
- Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on etiology, diagnosis, management and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648.
- Lancaster ST, Koons KL, Lee YJ, et al. Acute autoimmune myocarditis as a manifestation of graves’ disease: a case report and review of the literature. Clin Case Rep. 2019;7(8):1489–1493.
- Ekbom K, Krabbe A, Micelli G, et al. Cluster headache attacks treated for up three months with subcutaneous sumatriptan (6 mg). Cephalalgia. 1995;15(3):230–236.
- Napoli R, Biondi B, Guardasole V, et al. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001;104(25):3076–3080.
- Brondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–443.
- Moderna. mRNA-1273 sponsor briefing document for Vaccines and Related Biological Products Advisory Committee (VRBPAC) FDA VRBPAC FDA; 2020 Dec 17. Available from: http://www.fda.gov/media/144452/download
- Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331–340.
- Lui DTW, Lee KK, Lee CH, et al. Development of Graves’ disease after SARS-CoV2 mRNA vaccination: a case report and literature review. Front Public Health. 2021;9(778964):1–8.